查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1471077

神经调节市场：按技术、按应用划分 - 2024-2030 年全球预测

Neuromodulation Market by Technology (Deep Brain Stimulation, Gastric Stimulation, Sacral Nerve Stimulation), Application (Chronic Pain, Dystonia, Essential Tremor) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年神经调节市场规模为77.6亿美元，预计2024年将达86.1亿美元，2030年将达到166.2亿美元，复合年增长率为11.50%。

神经调节设备和治疗方法旨在将电、化学或药剂输送到神经系统以调节其活动。该技术主要用于治疗多种疾病，包括慢性疼痛、癫痫、帕金森氏症和尿失禁。慢性疼痛和神经系统疾病的增加迫切需要神经调节治疗。此外，人们对神经调节技术益处的认识不断提高、医疗保健支出增加以及政府为促进神经系统治疗的努力而做出的努力，都有助于神经调节技术的广泛采用。然而，神经调节设备和系统的产品召回以及潜在的安全和健康风险阻碍了该技术的普及。此外，治疗的侵入性，加上有关医疗设备核准的严格规定，可能会减缓神经调节策略的采用。然而，主要企业正在研究非侵入性方法，以扩大患者覆盖范围并保持患者依从性。开发个人化神经调节疗法有可能满足个别患者的需求和生理学并提供更好的治疗结果。生物相容性材料的进步、引入无线技术来控制神经调节设备以及利用巨量资料分析来解释神经调节结果可能会为该技术的发展提供新的机会。

主要市场统计
基准年[2023] 77.6亿美元
预测年份 [2024] 86.1亿美元
预测年份 [2030] 166.2亿美元
复合年增长率（%） 11.50%

技术 对运动障碍和精神疾病的深部脑部刺激疗法的需求不断增长

深部脑部刺激 (DBS) 是治疗方法帕金森氏症、自发性震颤和肌张力不全症失调等运动障碍的方法。电极被植入大脑的特定区域，产生控制异常脉衝的电脉衝。 DBS 的需要通常是根据严重程度和对其他治疗的反应来决定。胃刺激疗法，也称为胃电刺激（GES），针对胃的肌肉和神经，通常用于治疗肥胖和胃轻瘫。当患者对传统治疗方法没有反应并需要替代干预措施来控制症状和体重时，就会出现这种需求。荐椎神经刺激主要用于治疗尿失禁和大便失禁。对保守治疗没有充分反应的失禁患者是 SNS 的候选者，SNS 使用可植入装置来电刺激荐骨神经。脊髓刺激是一种治疗慢性疼痛的策略，包括腰部手术失败症候群、复杂性局部疼痛症候群和慢性顽固性疼痛。当其他疼痛管理治疗无法提供足够的缓解时，可选择 SCS。它使用低压电刺激脊髓，在疼痛讯号到达大脑之前阻止它们。迷走神经刺激主要用于治疗癫痫和忧郁症。 VNS适用于不适合手术或对药物治疗有抵抗力的患者。这种治疗方法会向迷走神经发送电脉衝以调节神经传递。

应用范例 帕金森氏症在全球范围内呈上升趋势

慢性疼痛治疗​​是神经调节的主要应用领域之一。脊髓刺激设备(SCS) 等设备可以透过向脊髓发送电脉衝来显着减轻疼痛。药物治疗的限制和避免长期使用鸦片类药物的愿望产生了基于需求的偏好。肌张力不全症的神经调节通常涉及深部脑部刺激（DBS）以减少不自主的肌肉收缩。患者的偏好取决于手术的安全性以及药物治疗不足时症状改善的潜力。特发性震颤通常以针对丘脑的 DBS 系统来治疗，以抑制震颤症状。对药物治疗无反应的患者对此类系统的需求正在增加。胃轻瘫的特征是排放延迟，可以透过胃电刺激来治疗。对于对传统治疗没有反应的患者，强迫性精神官能症(OCD) 可以透过 DBS 进行治疗，DBS 的目标是与疾病相关的大脑区域。 DBS主要用于透过神经调节来治疗帕金森氏症，可以缓解僵硬、心搏过缓缓和震颤等症状。当即使经过药物治疗运动症状也没有改善时选择它。顽固性癫痫的神经调节包括迷走神经刺激（VNS）和反应性神经刺激（RNS）。这些治疗方法适用于不适合手术或患有难治性癫痫的患者。迷走神经刺激可有效抗治疗性忧郁症(TRD)，并有助于调节情绪和情绪调节途径。当多种抗忧郁症不能提供足够的临床疗效时选择它。骶神经调节可有效治疗尿失禁和大便失禁，并且由于有效的药物选择有限而获得认可。

区域洞察

架构区域以美国和加拿大为中心，其特点是强大的医疗保健架构以及有利的报销和保险政策，这些政策正在影响神经调节技术的采用。此外，该地区对神经和心理健康问题的认识很高，这也推动了该技术在患者中的认可。患者情况反映了对 FDA 批准的创新治疗方法的偏好以及采用新技术的意愿。随着公司和研究机构寻求扩大神经调节治疗的功效和范围，美洲地区正在神经调节领域进行持续的研究和大量投资，并拥有强大的专利格局。在欧盟（EU），预期寿命的延长和有利的报销政策是推动神经调节市场需求的关键因素。患者的需求集中在人口老化中普遍存在的慢性病的管理上，而客户的购买行为则受到公共医疗系统提供的医疗保险的影响。重点是在整个欧盟范围内制定通用标准和法规，以放宽市场准入并确保病患安全。欧盟的特点是严格的医疗保健法规，这正在推动创新以提高神经调节技术的安全性和准确性。随着印度和中国等国家神经系统疾病的增加，以及日本人口的快速老化，对神经调节治疗的需求日益增长。政府为意识提升和改善医疗基础设施所做的努力正在推动亚太地区神经调节的成长。

FPNV定位矩阵

FPNV定位矩阵对于评估神经调节市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对神经调节市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1. 神经调节市场的市场规模与预测是多少？

2.在神经调节市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3. 神经调控市场的技术趋势和法规结构是什么？

4.神经调节市场主要厂商的市场占有率是多少？

5. 进入神经调节市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人口老化和神经系统疾病在世界各地变得越来越普遍。
      • 神经刺激系统和解决方案的研究倡议和临床试验
      • 政府努力扩大神经系统疾病和失调的治疗方法机会
    • 抑制因素
      • 神经调节和神经刺激设备或系统的产品回收数量
    • 机会
      • 优化神经调节策略效率与安全性的创新
      • 世界各地正在核准神经调节设备和治疗方法
    • 任务
      • 该技术的侵入性和技术限制
  • 市场区隔分析
    • 技术：针对运动障碍和精神疾病的深部脑部刺激疗法的需求正在增长
    • 应用：全球帕金森氏症发生率增加
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章神经调节市场：依技术分类

  • 脑深部电刺激疗法
  • 胃刺激
  • 荐椎神经刺激
  • 脊髓刺激
  • 迷走神经刺激

第七章神经调节市场：依应用分类

  • 慢性疼痛
  • 肌张力不全症
  • 自发性震颤
  • 胃轻瘫
  • 强迫性精神官能症
  • 帕金森氏症
  • 难治性癫痫
  • 抗治疗性忧郁症
  • 尿失禁

第八章美洲神经调节市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区神经调节市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲的神经调节市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • GrayMatters Health 在美国推出经 FDA核准的新的自动神经调节 PTSD治疗方法
    • Dr Reddy's 在印度推出用于偏头痛管理的可穿戴设备
    • Galderma 在 Liquid实况活动中展示了大胆的神经调节雄心
  • 战略分析和建议

第12章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-036C5CF3B4DB

[180 Pages Report] The Neuromodulation Market size was estimated at USD 7.76 billion in 2023 and expected to reach USD 8.61 billion in 2024, at a CAGR 11.50% to reach USD 16.62 billion by 2030.

Neuromodulation devices and therapies are designed to deliver targeted electrical, chemical, or pharmaceutical agents to the nervous system in order to modulate its activity. This technology is primarily used for the treatment of various disorders, such as chronic pain, epilepsy, Parkinson's disease, and urinary incontinence, among others. Growing incidences of chronic pain and neurological disorders have created an urgent need for neuromodulation treatments. Furthermore, increased awareness about the benefits of neuromodulation techniques, rising healthcare expenditure, and government initiatives to promote access to neurological therapies are contributing to the growing adoption of neuromodulation. However, incidences of product recall of neuromodulation devices and systems and the possibility of safety and health risks hamper the widespread growth of the technology. Additionally, the invasiveness of the therapy, coupled with strict regulations regarding the approval of medical devices, can delay the adoption of neuromodulation strategies. However, key players are researching non-invasive methods to expand the patient reach and maintain patient compliance. Developing personalized neuromodulation therapies could provide superior outcomes by catering to individual patient needs and physiology. Advances in biocompatible materials, incorporating wireless technologies to control neuromodulation devices, and utilizing big data analytics to interpret neuromodulation outcomes can provide new opportunities for the growth of the technology.

KEY MARKET STATISTICS
Base Year [2023] USD 7.76 billion
Estimated Year [2024] USD 8.61 billion
Forecast Year [2030] USD 16.62 billion
CAGR (%) 11.50%

Technology: Increasing need for deep brain stimulation therapies for movement disorders and psychiatric issues

Deep brain stimulation (DBS) is a treatment for targeting movement disorders such as Parkinson's disease, essential tremor, and dystonia. It involves the implantation of electrodes within certain areas of the brain, producing electrical impulses that regulate abnormal impulses. The need for DBS is generally based on the severity and responsiveness of the condition to other treatments. Gastric stimulation, also known as gastric electrical stimulation (GES), targets the stomach's muscles and nerves and is typically used for treating obesity and gastroparesis. The need arises when patients are unresponsive to traditional treatments and require alternative interventions to manage symptoms or weight. Sacral nerve stimulation is mainly used to treat urinary and fecal incontinence. Patients with incontinence who do not respond adequately to conservative therapies may be candidates for SNS, which involves the electrical stimulation of the sacral nerve through an implantable device. Spinal cord stimulation is a treatment strategy for chronic pain situations, including failed back surgery syndrome, complex regional pain syndrome, and chronic intractable pain. SCS is chosen when other pain management therapies fail to provide sufficient relief. It involves the delivery of low-voltage electrical stimulation to the spinal cord, which then blocks pain signals before they reach the brain. Vagus nerve stimulation is primarily used for the treatment of epilepsy and depression. VNS is considered for patients who are not suitable for surgery and whose conditions are refractory to medication. The therapy delivers electrical impulses to the vagus nerve to modulate neurotransmission.

Application: Rising incidences of Parkinson's disease across the world

Chronic pain treatment is one of the primary applications of neuromodulation. Devices such as spinal cord stimulators (SCS) can provide significant pain relief by sending electrical impulses to the spinal cord. Need-based preference emerges from the limitations of pharmacological treatments and the desire to avoid long-term opioid use. Neuromodulation for dystonia often involves deep brain stimulation (DBS) to reduce involuntary muscle contractions. Patient preference relies on procedural safety and the possibility of symptom improvement when medications are not adequate. Essential tremor is commonly addressed with DBS systems targeting the thalamus to suppress tremor symptoms. The need for these systems rises among patients who are unresponsive to medications. Gastroparesis, characterized by delayed stomach emptying, can be treated with gastric electrical stimulation. Obsessive-compulsive disorder (OCD) can be managed with DBS, targeting brain regions linked to the disorder for patients who don't respond to conventional treatment. Parkinson's disease treatment through neuromodulation mainly involves DBS, which can alleviate symptoms such as rigidity, bradykinesia, and tremor. This option becomes a preference when patients experience motor symptoms despite medication. Neuromodulation for refractory epilepsy includes vagus nerve stimulation (VNS) and responsive neurostimulation (RNS). These therapies are indicated for patients not suitable for surgery or those with intractable epilepsy. Treatment-resistant depression (TRD) can benefit from vagus nerve stimulation, which helps in modulating mood and emotional regulation pathways. Preference arises when multiple antidepressants fail to provide adequate clinical benefits. Sacral neuromodulation is effective for managing urinary and fecal incontinence, with acceptance increasing due to limited effective pharmaceutical options.

Regional Insights

The Americas region, particularly the U.S. and Canada, is characterized by the presence of a robust healthcare architecture and favorable reimbursement and insurance policies, which has shaped the adoption of neuromodulation technologies. Additionally, the awareness regarding neurological disorders and mental health issues is high in this region, thereby driving the recognition of the technology among patients. The patient landscape reflects a preference for innovative, FDA-approved treatments and a willingness to adopt new technologies. The Americas region exhibits a robust patent landscape with ongoing research and substantial investments in the neuromodulation space, as companies and research institutions aim to advance the efficacy and scope of neuromodulation therapies. In the European Union, increased life expectancy and favorable reimbursement policies are significant factors driving the need for the neuromodulation market. Patient needs are centered around the management of chronic conditions prevalent in an aging population, and customer purchasing behavior is influenced by the healthcare coverage provided by public health systems. There is a focus on creating common standards and regulations across the EU to facilitate market access and ensure patient safety. The EU is characterized by stringent healthcare regulations, which have fuelled several innovations to improve the safety and precision of neuromodulation technologies. The increasing incidences of neurological diseases in countries such as India and China and a rapidly aging population in Japan have augmented the need for neuromodulation therapies. Health awareness and government initiatives to advance the healthcare infrastructure can create a robust ground for the growth of neuromodulation in the APAC region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Neuromodulation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Neuromodulation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Neuromodulation Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, BioControl by Merck, BioElectronics Corporation, Boston Scientific Corporation, Dr Reddys Laboratories Limited, EndoStim, Inc., Galderma S.A., GrayMatters Health, Impulse Dynamics, Livanova, Mainstay Medical, Medtronic PLC, MicroTransponde, NeuroMetrix, Neuronetics, Inc., NeuroPace, Inc., NeuroSigma, Inc., Nevro Corp., Saluda Medical, SceneRay Corporation, Limited, Soterix Medical, and Synapse Biomedical.

Market Segmentation & Coverage

This research report categorizes the Neuromodulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Deep Brain Stimulation
    • Gastric Stimulation
    • Sacral Nerve Stimulation
    • Spinal Cord Stimulation
    • Vagus Nerve Stimulation
  • Application
    • Chronic Pain
    • Dystonia
    • Essential Tremor
    • Gastroparesis
    • Obsessive Compulsive Disorder
    • Parkinson's Disease
    • Refractory Epilepsy
    • Treatment Resistant Depression
    • Urinary Fecal Incontinence
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Neuromodulation Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Neuromodulation Market?

3. What are the technology trends and regulatory frameworks in the Neuromodulation Market?

4. What is the market share of the leading vendors in the Neuromodulation Market?

5. Which modes and strategic moves are suitable for entering the Neuromodulation Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the aging population across the world and prevalence of neurological disorders
      • 5.1.1.2. Research initiatives and clinical trials for neurostimulation systems and neuromodulation solutions
      • 5.1.1.3. Government initiatives to expand access to therapies for neurological diseases and disorders
    • 5.1.2. Restraints
      • 5.1.2.1. Incidences of product recall of neuromodulation and neurostimulation devices or systems
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations to optimize the efficiency and safety of neuromodulation strategies
      • 5.1.3.2. Ongoing approvals for neuromodulation devices and treatments across the world
    • 5.1.4. Challenges
      • 5.1.4.1. Invasiveness and technical limitations of the technology
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Increasing need for deep brain stimulation therapies for movement disorders and psychiatric issues
    • 5.2.2. Application: Rising incidences of Parkinson's disease across the world
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Neuromodulation Market, by Technology

  • 6.1. Introduction
  • 6.2. Deep Brain Stimulation
  • 6.3. Gastric Stimulation
  • 6.4. Sacral Nerve Stimulation
  • 6.5. Spinal Cord Stimulation
  • 6.6. Vagus Nerve Stimulation

7. Neuromodulation Market, by Application

  • 7.1. Introduction
  • 7.2. Chronic Pain
  • 7.3. Dystonia
  • 7.4. Essential Tremor
  • 7.5. Gastroparesis
  • 7.6. Obsessive Compulsive Disorder
  • 7.7. Parkinson's Disease
  • 7.8. Refractory Epilepsy
  • 7.9. Treatment Resistant Depression
  • 7.10. Urinary Fecal Incontinence

8. Americas Neuromodulation Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Neuromodulation Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Neuromodulation Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. GrayMatters Health Launches New FDA-Cleared Self-Neuromodulation PTSD Therapy in the United States
    • 11.3.2. Dr. Reddy's Unveils Wearable for Migraine Management in India
    • 11.3.3. Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. NEUROMODULATION MARKET RESEARCH PROCESS
  • FIGURE 2. NEUROMODULATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEUROMODULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. NEUROMODULATION MARKET DYNAMICS
  • FIGURE 7. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES NEUROMODULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES NEUROMODULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. NEUROMODULATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. NEUROMODULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEUROMODULATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEUROMODULATION MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL NEUROMODULATION MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTRIC STIMULATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTRIC STIMULATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL NEUROMODULATION MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEUROMODULATION MARKET SIZE, BY DYSTONIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL NEUROMODULATION MARKET SIZE, BY DYSTONIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEUROMODULATION MARKET SIZE, BY ESSENTIAL TREMOR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL NEUROMODULATION MARKET SIZE, BY ESSENTIAL TREMOR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTROPARESIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL NEUROMODULATION MARKET SIZE, BY GASTROPARESIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEUROMODULATION MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL NEUROMODULATION MARKET SIZE, BY OBSESSIVE COMPULSIVE DISORDER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEUROMODULATION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL NEUROMODULATION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEUROMODULATION MARKET SIZE, BY REFRACTORY EPILEPSY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL NEUROMODULATION MARKET SIZE, BY REFRACTORY EPILEPSY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEUROMODULATION MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL NEUROMODULATION MARKET SIZE, BY TREATMENT RESISTANT DEPRESSION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEUROMODULATION MARKET SIZE, BY URINARY FECAL INCONTINENCE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL NEUROMODULATION MARKET SIZE, BY URINARY FECAL INCONTINENCE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS NEUROMODULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 51. BRAZIL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 52. BRAZIL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES NEUROMODULATION MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES NEUROMODULATION MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 74. AUSTRALIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. AUSTRALIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. CHINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 78. CHINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 79. CHINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. CHINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. INDIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 82. INDIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 83. INDIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. INDIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. INDONESIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 86. INDONESIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 87. INDONESIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. INDONESIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. JAPAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 90. JAPAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 91. JAPAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. JAPAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. MALAYSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 94. MALAYSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 95. MALAYSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. MALAYSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 98. PHILIPPINES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. PHILIPPINES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. SINGAPORE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 102. SINGAPORE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 103. SINGAPORE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 104. SINGAPORE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 106. SOUTH KOREA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. SOUTH KOREA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. TAIWAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 110. TAIWAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 111. TAIWAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. TAIWAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. THAILAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 114. THAILAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 115. THAILAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. THAILAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. VIETNAM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 118. VIETNAM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 119. VIETNAM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. VIETNAM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA NEUROMODULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 127. DENMARK NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 128. DENMARK NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 129. DENMARK NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 130. DENMARK NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 131. EGYPT NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 132. EGYPT NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 133. EGYPT NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. EGYPT NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. FINLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 136. FINLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 137. FINLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. FINLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. FRANCE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 140. FRANCE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 141. FRANCE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 142. FRANCE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 143. GERMANY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 144. GERMANY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 145. GERMANY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. GERMANY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. ISRAEL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 148. ISRAEL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 149. ISRAEL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. ISRAEL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. ITALY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 152. ITALY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 153. ITALY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. ITALY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. NETHERLANDS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 156. NETHERLANDS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 157. NETHERLANDS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 158. NETHERLANDS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 159. NIGERIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 160. NIGERIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 161. NIGERIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. NIGERIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. NORWAY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 164. NORWAY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 165. NORWAY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. NORWAY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. POLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 168. POLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 169. POLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. POLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. QATAR NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 172. QATAR NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 173. QATAR NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. QATAR NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. RUSSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 176. RUSSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 177. RUSSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. RUSSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. SAUDI ARABIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 180. SAUDI ARABIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 181. SAUDI ARABIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 182. SAUDI ARABIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 183. SOUTH AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 184. SOUTH AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 185. SOUTH AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. SOUTH AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. SPAIN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 188. SPAIN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 189. SPAIN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. SPAIN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. SWEDEN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 192. SWEDEN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 193. SWEDEN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. SWEDEN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. SWITZERLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 196. SWITZERLAND NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 197. SWITZERLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 198. SWITZERLAND NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 199. TURKEY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 200. TURKEY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 201. TURKEY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 202. TURKEY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 203. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 204. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 205. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 206. UNITED ARAB EMIRATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 207. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 208. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 209. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. NEUROMODULATION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 212. NEUROMODULATION MARKET, FPNV POSITIONING MATRIX, 2023